Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Sep;32(3):295–302. doi: 10.1111/j.1365-2125.1991.tb03902.x

Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man.

M G Ladona 1, B Lindström 1, C Thyr 1, P Dun-Ren 1, A Rane 1
PMCID: PMC1368521  PMID: 1838002

Abstract

1. Codeine and dextromethorphan were N-demethylated in human foetal liver microsomes at high rates which were close to the activities in adult livers. In contrast, foetal liver microsomes did not catalyze the O-demethylation of these drugs at mid-gestation. 2. The metabolic data were in accordance with the absence of P450IID6 and the presence of P450 IIIA as determined by Western blotting with anti-human P450 IID6 (MAb 114/2) and anti-rat P450 IIIA (PCN 2-13-1/C2) monoclonal antibodies, respectively. 3. The inhibitory effects of midazolam and dehydroepiandrosterone support the contention that the N-demethylase is a human foetal form of the cytochrome P450 IIIA family. Consistent with this we found that blotting with the MAb PCN 2-13-1/C2, which recognizes an epitope specific for the P450 III family, correlated well with the N-demethylase activities.

Full text

PDF
295

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989;36(6):537–547. doi: 10.1007/BF00637732. [DOI] [PubMed] [Google Scholar]
  2. Chen Z. R., Somogyi A. A., Bochner F. Polymorphic O-demethylation of codeine. Lancet. 1988 Oct 15;2(8616):914–915. doi: 10.1016/s0140-6736(88)92529-9. [DOI] [PubMed] [Google Scholar]
  3. Davies D. S., Kahn G. C., Murray S., Brodie M. J., Boobis A. R. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol. 1981 Jan;11(1):89–91. doi: 10.1111/j.1365-2125.1981.tb01108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun. 1988 Apr 15;152(1):411–416. doi: 10.1016/s0006-291x(88)80729-0. [DOI] [PubMed] [Google Scholar]
  5. Dayer P., Kronbach T., Eichelbaum M., Meyer U. A. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol. 1987 Dec 1;36(23):4145–4152. doi: 10.1016/0006-2952(87)90573-9. [DOI] [PubMed] [Google Scholar]
  6. Eichelbaum M., Woolhouse N. M. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol. 1985;28(1):79–83. doi: 10.1007/BF00635712. [DOI] [PubMed] [Google Scholar]
  7. Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988 Feb 4;331(6155):442–446. doi: 10.1038/331442a0. [DOI] [PubMed] [Google Scholar]
  8. Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol Rev. 1988 Dec;40(4):243–288. [PubMed] [Google Scholar]
  9. Guengerich F. P., Müller-Enoch D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986 Sep;30(3):287–295. [PubMed] [Google Scholar]
  10. Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H. H., Zhou B. I., Liao C. L., Zhang L. M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989 Aug;46(2):198–207. doi: 10.1038/clpt.1989.126. [DOI] [PubMed] [Google Scholar]
  11. Idle J. R., Smith R. L. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979;9(2):301–317. doi: 10.3109/03602537908993896. [DOI] [PubMed] [Google Scholar]
  12. Kitada M., Kamataki T., Itahashi K., Rikihisa T., Kanakubo Y. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem. 1987 Oct 5;262(28):13534–13537. [PubMed] [Google Scholar]
  13. Komori M., Nishio K., Ohi H., Kitada M., Kamataki T. Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. J Biochem. 1989 Feb;105(2):161–163. doi: 10.1093/oxfordjournals.jbchem.a122632. [DOI] [PubMed] [Google Scholar]
  14. Kroemer H. K., Mikus G., Kronbach T., Meyer U. A., Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther. 1989 Jan;45(1):28–33. doi: 10.1038/clpt.1989.5. [DOI] [PubMed] [Google Scholar]
  15. Kronbach T., Fischer V., Meyer U. A. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988 Jun;43(6):630–635. doi: 10.1038/clpt.1988.87. [DOI] [PubMed] [Google Scholar]
  16. Kronbach T., Mathys D., Umeno M., Gonzalez F. J., Meyer U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989 Jul;36(1):89–96. [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Ladona M. G., Park S. S., Gelboin H. V., Hammar L., Rane A. Monoclonal antibody directed detection of cytochrome P-450 (PCN) in human fetal liver. Biochem Pharmacol. 1988 Dec 15;37(24):4735–4741. doi: 10.1016/0006-2952(88)90345-0. [DOI] [PubMed] [Google Scholar]
  19. Ladona M. G., Spalding D. J., Ekman L., Linström B., Rane A. Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P-450 PCN and interactions with important fetal corticosteroids. Biochem Pharmacol. 1989 Oct 1;38(19):3147–3155. doi: 10.1016/0006-2952(89)90607-2. [DOI] [PubMed] [Google Scholar]
  20. Leemann T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol. 1986;29(6):739–741. doi: 10.1007/BF00615971. [DOI] [PubMed] [Google Scholar]
  21. Meyer U. A., Gut J., Kronbach T., Skoda C., Meier U. T., Catin T., Dayer P. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica. 1986 May;16(5):449–464. doi: 10.3109/00498258609050251. [DOI] [PubMed] [Google Scholar]
  22. Mortimer O., Persson K., Ladona M. G., Spalding D., Zanger U. M., Meyer U. A., Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther. 1990 Jan;47(1):27–35. doi: 10.1038/clpt.1990.4. [DOI] [PubMed] [Google Scholar]
  23. Nebert D. W., Nelson D. R., Adesnik M., Coon M. J., Estabrook R. W., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Kemper B. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA. 1989 Jan-Feb;8(1):1–13. doi: 10.1089/dna.1.1989.8.1. [DOI] [PubMed] [Google Scholar]
  24. Rane A., Gawronska-Szklarz B., Svensson J. O. Natural (-)- and unnatural (+)-enantiomers of morphine: comparative metabolism and effect of morphine and phenobarbital treatment. J Pharmacol Exp Ther. 1985 Sep;234(3):761–765. [PubMed] [Google Scholar]
  25. Rice K. C. An improved procedure of the n-demethylation of 6,7-benzomorphans, morphine, and codeine. J Org Chem. 1975 Jun 13;40(12):1850–1851. doi: 10.1021/jo00900a044. [DOI] [PubMed] [Google Scholar]
  26. Schmid B., Bircher J., Preisig R., Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 1985 Dec;38(6):618–624. doi: 10.1038/clpt.1985.235. [DOI] [PubMed] [Google Scholar]
  27. Siddoway L. A., Thompson K. A., McAllister C. B., Wang T., Wilkinson G. R., Roden D. M., Woosley R. L. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987 Apr;75(4):785–791. doi: 10.1161/01.cir.75.4.785. [DOI] [PubMed] [Google Scholar]
  28. Skoda R. C., Gonzalez F. J., Demierre A., Meyer U. A. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5240–5243. doi: 10.1073/pnas.85.14.5240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Watkins P. B., Wrighton S. A., Maurel P., Schuetz E. G., Mendez-Picon G., Parker G. A., Guzelian P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6310–6314. doi: 10.1073/pnas.82.18.6310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Woolhouse N. M. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians. Prog Clin Biol Res. 1986;214:189–206. [PubMed] [Google Scholar]
  31. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645. doi: 10.1111/j.1365-2125.1989.tb03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Zanger U. M., Vilbois F., Hardwick J. P., Meyer U. A. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry. 1988 Jul 26;27(15):5447–5454. doi: 10.1021/bi00415a010. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES